Tessel Biosciences develops virtual tissues to accelerate drug design and discovery. Their platform enables researchers to model complex biological systems outside of traditional in vivo or in vitro settings. This approach provides a scalable method for testing therapeutic candidates with greater predictive accuracy.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery often fails to translate from traditional in vitro or animal models to humans due to the limitations of replicating human physiology. This can lead to ineffective drug candidates and delayed treatments for diseases characterized by tissue remodeling, particularly in the lung.
Solution
Tessel Biosciences leverages patient-derived tissues and a proprietary platform, Tesselogic, to identify and validate drug targets that more accurately reflect human physiology. By measuring physiological phenotypes in vitro, such as mucus transport in lung tissue, Tessel can optimize drug candidates for diseases like COPD. The platform uses active learning algorithms to efficiently map molecular states to tissue function, enabling the discovery of drug targets with a higher likelihood of clinical translation.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for chronic diseases, particularly those involving tissue remodeling.
Features
- Uses patient-derived tissues to model human physiology in drug discovery.
- Tesselogic platform employs active learning algorithms for efficient target discovery.
- Measures physiological phenotypes, such as mucus transport, in organotypic cultures.
- Maps molecular states to tissue function to identify translatable drug targets.
- Focuses on diseases characterized by tissue remodeling, starting with lung diseases.